Scienta Lab

Since our inception in 2021, we have been driven by a single mission: bringing precision immunology to patients with immune conditions. Today, we are excited to announce a strategic partnership with OSE Immunotherapeutics, a leading European biotech, to harness the Scienta Lab technological platform in pursuit of this goal. Within the collaboration, we will deploy EVA, our foundation model for immunology and inflammation, alongside Explainable AI pipelines to stratify immuno-inflammatory diseases into distinct subtypes based on multimodal signatures. This approach will support the identification of patient subgroups most likely to benefit from targeted therapeutic options. Shoutout to the OSE team Nicolas Poirier, Fiona Olivier, Aurore Morello and Isabelle Girault for their outstanding work. Let’s make it happen together! For more details, check out the press release: https://lnkd.in/eknwPcjg

As the AI Action Summit Week is about to kick off, we’re starting strong with this must-attend event ! Meet Julien Duquesne, CTO & co-founder of Scienta Lab, at the Yseop event on the role of AI in transforming clinical R&D : Date: February 5, 2025 Time: 3:00 PM - 6:00 PM Location: CentraleSupélec, Paris-Saclay Campus This event brings together leading experts, researchers, and innovators to discuss key challenges and breakthroughs in clinical research, including: - Data Access & Security: A deep dive into health data warehouses, open data initiatives, and best practices for protecting and managing sensitive data - AI Efficiency & Performance: Exploring AI techniques, the orchestration of AI agents, and the strategic role of Small Language Models to balance efficiency and sustainability in specific use cases - Evaluation & Transparency: Understanding healthcare-specific requirements, evaluation criteria, and the challenges of automation and auditability in clinical assessments Program and registration : https://lnkd.in/eYcWNYQX Mathieu Jeandron Caroline Beaufour Olivier Teboul Hakim Benkirane Alain Kaeser Pierre-Louis Durel Celine Hudelot #AIActionSummit #SemaineActionIA

Interested in learning How Scienta Lab’s foundation model offers a path to precision medicine in immunology and inflammation? Meet our CEO & co-founder Camille Bouget next week at the J.P. Morgan 43rd Healthcare Conference in San Francisco!

📢 IHI-funded AutoPiX project Scienta Lab is joining forces with world-class pharmaceutical and medical technology partners and leading academic institutions to improve the diagnosis, treatment decisions, and monitoring of major rheumatic diseases as part of the IHI-funded AutoPix-project. Project Key Facts ·         Full Name: IHI-AUTOPIX - Imaging for patient benefit in arthritis ·         Start date: 1st November 2024 ·         Duration: 60 months ·         Budget: 20 Mil. € ·         Coordinator: Medical University of Vienna, Prof. Dr Daniel Aletaha, Assoc. Prof. Dr. Peter Mandl MD, PhD ·         Project Leader: Johnson & Johnson, Rob Janiczek, PhD

🎤🗓️ Scienta Lab is pleased to announce that the results of its latest research on the molecular stratification of Sjögren’s Disease, conducted in collaboration with Servier, will be presented at the American College of Rheumatology 2024 Convergence Conference in Washington, DC. In an oral presentation, Vincent Bouget, our co-founder and CSO, will demonstrate how we’ve leveraged our proprietary foundation model, EVA, to identify molecular biomarkers for Sjögren’s Disease stratification. These findings shed new light on disease heterogeneity and pave the way for more precise, targeted therapeutic strategies. During this session, Vincent will also provide an update on our second project in the space: a multicenter validation of a machine learning foundation model to diagnose Sjögren’s disease and identify histological biomarkers for disease stratification. Join us at the ACR Convergence on Monday, November 18th, at 3:00 PM (Room 103AB, Washington Convention Center) for these insightful presentations! Press release available in the comment section 👇

🧪🧫 Utiliser l’intelligence artificielle pour mieux comprendre les maladies inflammatoires et auto-immunes et pouvoir ainsi développer des traitements plus efficaces. 👉 C’est tout l’enjeu de la startup Scienta Lab, cofondée par Julien Duquesne, CTO, Vincent Bouget, CSO – tous deux diplômés de CentraleSupélec – et Camille Bouget, CEO, docteure en pharmacie passée par l’industrie pharmaceutique. Mon interview de Julien Duquesne est à retrouver ici https://urlz.fr/sWl3 CentraleSupélec 21st by CentraleSupélec

Interested in learning how Scienta Lab trained a foundation model from scratch to understand the links between some dermatological autoimmune diseases? Read our blog post below ⏬ In summary : • Data: We used private electronic health record from the UK database OPCRD, gathering 2.7 million of patients suffering from immune-mediated inflammatory diseases. • Model and training method: We trained a Transformer model on a classic MLM task and tweaked the model to specify it to our needs  • Analysis: We extracted ~ 50k patients suffering from dermatological immune diseases. We used our trained model to compute their embeddings and cluster them.  • Results: Our model managed to grasp the diseases continuum and to isolate subgroups of patients within a given disease, opening the path for targeted therapeutic approaches. PS: If you'd like to be part of the adventure by helping to push forward Scienta Lab's technological capabilities ➡️ Julien Duquesne is hiring, drop him a note on Linkedin ;)

We are pleased to announce that our co-founder & CEO Camille Bouget will present our research work in IBD, leveraging our foundation model EVA to identify and validate therapeutic targets, at the 2024 American College of Gastroenterology Annual Scientific Meeting in Philadelphia, PA! 🔬 Key Highlights: •Scope: EVA was used to construct distinct gene regulatory networks representing healthy individuals and IBD patients, leading to the identification of 20 therapeutic targets. •Impact: 10 of these genes showed strong links to existing drug targets, highlighting the potential to advance more effective, personalized therapies for IBD conditions such as Crohn’s disease and ulcerative colitis. •Recognition: Our research has been honoured with the prestigious Presidential Poster Award, which is granted to only about 5% of accepted abstracts annually for their high quality and innovative contributions. 📍 Join Us at ACG 2024: Poster Title: “Identification of New Therapeutic Targets in IBD Using a Transcriptomic Foundation Model” Date & Time: Tuesday, October 29th, 10:30 AM – 4:00 PM Location: Pennsylvania Convention Center, Philadelphia, PA, USA We look forward to sharing our vision for more personalized and targeted therapies that have the potential to transform patient care! Press release available in the comment section 👇

🏆 Exciting news: We’re proud to announce that Scienta Lab has been named a laureate of the I-Lab 2024 French Innovation Contest! This prestigious innovation competition supports groundbreaking startups transforming scientific research into impactful, market-ready solutions. We’re honored to be part of a group of 64 companies shaping the future with the support of #France2030. This recognition strengthens our mission to lead the AI-powered Precision immunology revolution thanks to EVA, our multimodal foundation model dedicated to immunology & inflammation. A big thanks to Bpifrance and the French Gouvernement for their continued support!    Secretary general for investment | ministere economie | Ministère de l'Enseignement supérieur et de la Recherche | Ministère de la Santé | Direction générale de la recherche et de l'innovation (DGRI) | Agence de l'innovation en santé

Attending the Annual Congress of the Swiss Society of Rheumatology in Lausanne on September 5? Come say hi to our CSO Vincent Bouget and chat about the impact of AI in rheumatology !